CONRAY 60 Rx
Generic Name and Formulations:
Iothalamate meglumine 600mg/mL; soln for IV infusion; organically bound iodine 282mg/mL.
Indications for CONRAY 60:
For use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, IV digital subtraction angiography and arterial digital subtraction angiography. For enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.
Review procedure precautions and adverse reactions prior to administration. Excretory urography: >14yrs: 30–60mL IV. Cerebral angiography: Carotid or vertebral angiography: single rapid inj of 6–10mL; Retrograde brachial cerebral angiography: single rapid inj of 35–50mL into the right brachial artery. Peripheral arteriography or venography: a single rapid inj of 20–40mL. Arthrography: Inject into joint. Knee, hip: 5–15mL; Shoulder, ankle: 5–10mL; Other: 1–4mL. Direct cholangiography: Operative: usual dose is 10mL but as much as 25mL may be needed depending upon the caliber of the ducts; Postoperative: injection usually made through an in-place T-tube; dose same as for operative cholangiography; Percutaneous transhepatic choliangiography: 20–40mL is generally sufficient to opacity the entire ductal system. Endoscopic retrograde cholangiopancreatography: inject slowly under fluoroscopic control; usual range: 10–100mL for visualization of common bile duct; 2–10mL for visualization of pancreatic duct. Contrast enhancement of CT brain imaging: 2mL/kg IV; max total dose 150mL. Cranial computerized angiotomography: 0.5–1mL/kg by bolus inj; max total dose per procedure 200mL. Contrast enhancement in body computed tomography: Vascular opacification: a bolus inj of 25–50mL may be used; repeat as necessary. IV digital subtraction angiography: may be injected centrally into superior vena cava or peripherally into an appropriate arm vein. Usual dose range: 20–40mL; inj may be repeated as necessary. Arterial digital subtraction angiography: usual doses: carotid or vertebral arteries: 3–8mL; Aortic arch: 15–25mL; Subclavian and brachial arteries: 5–15mL; Major branches of the aorta: 5–20mL; Lumbar aorta (bifurcation): 10–25mL.
Excretory urography: <6months: 5mL; 6–12months: 8mL; 1–2yrs: 10mL; 2–5yrs: 12mL; 5–8yrs: 15mL; 8–12yrs: 18mL; 12–14yrs: 20–30mL. Cerebral angiography, peripheral arteriography, venography, arthrography: dose dependent on age and weight. Contrast enhancement of CT brain imaging: 2mL/kg IV; max total dose 150mL. Cranial computerized angiotomography: 0.5–1mL/kg by bolus inj; max total dose per procedure 200mL.
Myelography. Others: see full labeling.
Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Avoid in homocystinuria. Subarachnoid hemorrhage. Multiple myeloma. Pheochromocytoma. Homozygous sickle cell disease. Primary or metastatic cerebral lesions; risk of convulsions. Advanced renal disease. Combined renal and hepatic disease. Severe hypertension. CHF. Recent renal transplant. Diabetes. Diabetic nephropathy. Hyperthyroidism. Endotoxemia. Elevated body temperatures. History of asthma/allergy. Elderly. Maintain adequate hydration. Pregnancy (Cat.B - Conray 30, 60; Cat.C - Conray 43). Nursing mothers: not recommended; avoid breastfeeding for 24hrs post-procedure.
Radiopaque contrast medium.
GI upset, facial flushing, body warmth; hypersensitivity reactions, cardiovascular reactions (eg, vasodilation, flushing, venospasm), inj site reactions, neurological reactions (eg, spasm, convulsions, aphasia, syncope, coma, death), endocrine reactions (eg, hypothyroidism), headache, shaking, chills, nephropathy.
Conray 30: Bottles (150mL)—12; Conray 43: Vials (50mL)—50; Bottles (250mL)—12; Conray 60: Vials (30mL, 50mL)—50; Bottles (100mL, 150mL)—12
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|